Description: Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
Exchange: BATS
Country: US
Currency: US Dollar ($)
Category: Health
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock US | 93.38 | 0.00 | 93.38 |
| Stock non-US | 6.62 | 0.00 | 6.62 |
| Cash | 0.00 | 0.00 | 0.00 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 96.57 | 99.57 |
| Technology | 3.42 | 0.13 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 95.27 | 92.60 |
| Europe Developed | 4.21 | 4.28 |
| United Kingdom | 0.52 | 1.65 |
| Japan | 0.00 | 0.54 |
| Australasia | 0.00 | 0.11 |
| Asia Emerging | 0.00 | 0.82 |
| Africa/Middle East | 0.00 | 0.02 |